Literature DB >> 21117386

The incretin system in the management of type 2 diabetes mellitus.

Jeffrey W Stephens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21117386      PMCID： PMC4952415          DOI： 10.7861/clinmedicine.10-5-491

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  36 in total

Review 1.  Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.

Authors:  Juris J Meier; Baptist Gallwitz; Michael A Nauck
Journal:  BioDrugs       Date:  2003       Impact factor: 5.807

2.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers.

Authors:  Michael A Nauck; Markus M Heimesaat; Kai Behle; Jens J Holst; Markus S Nauck; Robert Ritzel; Michael Hüfner; Wolff H Schmiegel
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

Review 3.  Overview of incretin hormones.

Authors:  S Efendic; N Portwood
Journal:  Horm Metab Res       Date:  2004 Nov-Dec       Impact factor: 2.936

4.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

Authors:  John B Buse; Robert R Henry; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

5.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

Review 6.  Incretin mimetics as emerging treatments for type 2 diabetes.

Authors:  Scott V Joy; Philip T Rodgers; Ann C Scates
Journal:  Ann Pharmacother       Date:  2004-11-23       Impact factor: 3.154

7.  Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

Authors:  Bo Ahrén; Ramon Gomis; Eberhard Standl; David Mills; Anja Schweizer
Journal:  Diabetes Care       Date:  2004-12       Impact factor: 19.112

Review 8.  Therapeutic strategies based on glucagon-like peptide 1.

Authors:  Carolyn F Deacon
Journal:  Diabetes       Date:  2004-09       Impact factor: 9.461

9.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Authors:  Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

Review 10.  The potential role of glucagon-like peptide 1 in diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Opin Investig Drugs       Date:  2004-04
View more
  1 in total

Review 1.  Diabetic autonomic neuropathy of the gastrointestinal tract.

Authors:  Edwin Kuźnik; Robert Dudkowiak; Rajmund Adamiec; Elżbieta Poniewierka
Journal:  Prz Gastroenterol       Date:  2020-06-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.